Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue - Takeaways - MDSpire

Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue

  • By

  • Eva Karaskova

  • David Friedecky

  • David Kleparnik

  • Adela Palkovska

  • Radana Brumarova

  • David Karasek

  • June 19, 2026

  • 0 min

Share

  • 1

    Patients with inflammatory bowel disease (IBD) have an increased risk of atherosclerotic cardiovascular disease (ASCVD) not fully explained by traditional risk factors.

  • 2

    Chronic systemic inflammation in IBD promotes endothelial dysfunction, hypercoagulability, and accelerated atherogenesis.

  • 3

    The 'lipid paradox' in IBD is characterized by reduced circulating lipid levels coexisting with increased cardiovascular risk due to inflammation-mediated lipid changes.

  • 4

    Dietary patterns associated with IBD contribute to gut dysbiosis, increased intestinal permeability, and chronic low-grade systemic inflammation.

  • 5

    Current strategies for assessing cardiovascular risk in IBD emphasize controlling disease activity and minimizing corticosteroid exposure.

Original Source(s)

Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue

  • by Eva Karaskova, David Friedecky, David Kleparnik, Adela Palkovska, Radana Brumarova, David Karasek

  • June 19, 2026

Related Content

Noncanonical NF-κB pathway driven inflammation across multiple cellular compartments identifies NIK as a therapeutic target for inflammatory bowel disease

Correction: Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation

3 Innovations Revolutionizing IBD Treatment

Keck Medicine of USC gastroenterologist Florence-Damilola (Damie) Odufalu, MD, shares how recent advances in inflammatory bowel disease treatment are changing the lives of patients.

  • by

  • May 26, 2026

  • 5 min